Solvias Capabilities Update October 2026: Analytical And Lab Services

From Lab to Launch: Analytical Testing Capabilities for Cell and Gene Therapy Development

Amy Glekas, PhD, Global Head of Field Development at Solvias, presents the company’s comprehensive analytical testing capabilities for cell and gene therapies, supporting developers from discovery and preclinical to commercial release. The presentation explores Solvias’ expertise across a broad range of advanced modalities, including viral vectors, mRNA and lipid nanoparticles, gene-editing tools, and cell-based therapies.

Glekas highlights integrated analytical solutions for critical quality attributes including identity, purity, potency, safety, and stability, as well as specialized capabilities for AAV characterization, mRNA and LNP analysis, gene-editing components, and cell-based assays. From advanced structural characterization and genomic analysis to method development, GMP release testing, and stability programs, the session demonstrates how Solvias combines scientific expertise, state-of-the-art technologies, and phase-appropriate testing strategies to address the complex analytical challenges of next-generation therapies and help customers advance their programs from lab to launch.